Accreditation Statistics

As of June 3, 2024

Cellular Therapy Entities

  • Accredited: 262
  • Applicants: 30

Cord Blood Banks

  • Accredited: 48
  • Applicants: 10

 

Initial Accreditations

  • Cord Blood Bank University Hospital Basel Cord Blood Collection (Fixed and Non-Fixed sites), Banking, and Release for Administration of Unrelated and Related Donations
  • Cord Blood Bank Geneva Cord Blood Collection (Fixed, Non-Fixed sites), Banking, and Release for Administration of Unrelated and Related Donations

     

A complete list of accredited organizations can be found at https://accredited.factglobal.org/.

Blood Advances Publishes Commentary on The Importance of a Quality Infrastructure for Immune Effector Cellular Therapy

Posted in :: 2024 Volume 3 :: Monday, June 24th, 2024

Blood Advances, the peer-review journal of the American Society of Hematology (ASH), published commentary from the FACT Immune Effector Cell Task Force regarding the importance of a quality infrastructure and how FACT accreditation can help.

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help (Curran, K., et. al, 2024), explains to a broad audience of hematology/oncology providers the importance of developing a quality system to deliver immune effector cell (IEC) therapy within its extremely complex patient and product journeys. In the context of FACT accreditation, the article outlines challenges that a verified quality system that meets peer-established requirements can alleviate.

We encourage our colleagues in the FACT community to share this article widely with departments, specialists, and practices that may be interested in providing IEC therapy to patients. Access to these groundbreaking therapies is only beneficial to patients if they are safe and effective. According to the article’s abstract:

“Immune effector cells (IECs) include a broad range of immune cells capable of modulating several disease states, including malignant and nonmalignant conditions. The growth in the use of IECs as both investigational and commercially available products requires medical institutions to develop workflows/processes to safely implement and deliver transformative therapy. Adding to the complexity of this therapy are the variety of targets, diseases, sources, and unique toxicities that a patient experiences following IEC therapy. For over 25 years, the Foundation for the Accreditation of Cellular Therapy (FACT) has established a standard for the use of cellular therapy, initially with hematopoietic cell transplantation (HCT), and more recently, with the development of standards to encompass IEC products such as chimeric antigen receptor (CAR)-T cells. To date, IEC therapy has challenged the bandwidth and infrastructure of the institutions offering this therapy. To address these challenges, FACT has established a programmatic framework to improve the delivery of IEC therapy. In this study, we outline the current state of IEC program development, accreditation, and solutions to the challenges that programs face as they expand their application to novel IEC therapy.”

Citation:

Kevin J. Curran, Sarah Nikiforow, Carlos Bachier, Yen-Michael Hsu, David Maloney, Marcela V. Maus, Philip McCarthy, David Porter, Patricia Shi, Elizabeth J. Shpall, Basem William, Kara Wacker, Phyllis Warkentin, Helen E. Heslop; A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help. Blood Adv 2024; 8 (4): 1053–1061. doi: https://doi.org/10.1182/bloodadvances.2023010401